Johnson & Johnson, entangled in talc cancer litigation, seems to have encountered new problems. According to a recent Reuters survey, Johnson is believed to be deliberately concealing diabetes drug Invokana causing the safety risk of ketoacidosis.
In March 2013, the US Food and Drug Administration (FDA) approved Johnson Invokana (calglie) for the treatment of adults with type 2 diabetes. The drug also became the first sodium glucose cotransporter 2 (SGLT2) inhibitor at that time. However, the drug has a series of safety warning labels, including lower limb amputation, dehydration and hypotension, the risk of genital yeast infection, severe allergic reaction and kidney problems, the most common of which is genital yeast infection.
Another possible side effect of the drug is ketoacidosis, which is a very serious complication of diabetes and may be life-threatening. It is worth noting that the US FDA did not begin to investigate ketoacidosis related to Johnson & Johnson invokana treatment until May 2015. Now, a Reuters survey believes that Johnson & Johnson knew in advance that invokana could lead to the risk of ketoacidosis, but the company deliberately covered up this side effect.
Merck is son of FDA:joy: 
